COMPARATIVE ANALYSIS OF TOTAL DISEASE COSTS IN PATIENTS WITH ARTERIAL HYPERTENSION: THE RESULTS OF THE OPEN, MULTI-CENTRE OBSERVATIONAL PROGRAMME “PRORYV”

Abstract

Aim. To compare total disease costs by the treatment regimen and blood pressure (BP) control levels among patients with arterial hypertension (AH). Material and methods. Pharmacoeconomic analyses of total disease costs were performed for two treatment regimens and 4115 patients participating in the open, multi-centre observational programme “PRORYV”: a retrospective cost analysis for the 12 pre-inclusion weeks and a prospective cost analysis for the 12 weeks of the programme participation. Results. The treatment with a fixed-dose combination of perindopril and amlodipine (Prestance) was more expensive for the patients than the pre-inclusion treatment (955,15±849,96 vs. 566,78±432,70 RUB per person per month). However, total direct costs for the Prestance-treated patients were 2,6 times lower (3164,07 vs. 8245,33 RUB per person for 12 weeks). Total treatment costs were also lower: 3463,47 vs. 14226,03 RUB per person for 12 weeks, respectively. Switching to a more effective treatment regimen (Prestance) modifies the distribution of the therapy costs, due to decreased incidence and duration of hospitalisation episodes and reduced number of medical visits and ambulance calls. Conclusion. The reduction in the AH treatment costs and modification of their distribution provides an opportunity for a wider use of more effective medications. Switching one patient from ineffective treatment to Prestance covers the costs of additional treatment of 310% patients (n=12757) for 12 weeks.